User talk:Janbaekelandt

Welcome!
Hello, Janbaekelandt, and welcome to Wikipedia! Thank you for your contributions. I hope you like the place and decide to stay. Here are some pages that you might find helpful:

I hope you enjoy editing here and being a Wikipedian! Please sign your messages on discussion pages using four tildes ( ~ ); this will automatically insert your username and the date. If you need help, check out Questions, ask me on my talk page, or ask your question and then place  before the question on your talk page.
 * Quick introduction to Wikipedia
 * How to write a great article
 * Ten Simple Rules for Editing Wikipedia, an essay from PLoS
 * Identifying reliable sources for medicine-related articles (general advice)
 * Wikipedia's Manual of Style for medicine-related articles (general style guide)

''If you are interested in medicine-related themes, you may want to check out the Medicine Portal. If you are interested in improving medicine-related articles, you may want to join WikiProject Medicine (sign up here or say hello here).''

Again, welcome! JFW &#124; T@lk  14:49, 3 August 2012 (UTC)

Dabigatran
Thank you for your additions to dabigatran. I have removed one of them, which is the observation from the FDA about the absolute number of adverse events. The source was a lot more balanced (see WP:NPOV), in the sense that it made a point about the fact that warfarin use might have led to a similar number of adverse events but they would not be reported to the FDA because it's been around since the 1960s. I would have no objection to returning the content, but only if it can be presented in a more neutral version. Perhaps you could provide some views on Talk:Dabigatran so we can discuss them there before going live. JFW &#124; T@lk  14:49, 3 August 2012 (UTC)


 * I have again removed the dubious claim about reporting. The claim about "unusually severe" bleeding looks highly circumstantial. One cannot infer that from the fact that most reports came from health professionals. Please discuss on Talk:Dabigatran. I am increasingly concerned that you are adding content in an unbalanced fashion from sources that fall short of the requirements from WP:MEDRS. JFW &#124; T@lk  22:44, 4 August 2012 (UTC)

JfdWolf I have great admiration for the work you do for wikipedia.

I agree with the removing of "suggesting that despite this well-known drug risk the bleeding was unexpected or unusually severe". Although, this is a sentance of the report. I don't agree with the removing of the whole paragraph. Because these are facts.

Is QuarterWatch a source that fal short of the reguirements of wikipedia??? Can you give one source that was used by me that fellt short of requirements from wikipedia??? Are the FDA reviewers and the EMA reviewers no good sources? Is the Canadian Therapeutics Letter no good source? What is unbalanced ?

I found it very unbalanced that the dabigatran article didn't mention that there is a serious bleeding risc for both warfarin and dabigatran; maybe a litle bit more for warfarin in the trial. But in real world in the US and in Western-Europe with good INR controle centers there is no difference.

In Pharmacovigilance i could ad the Australian Adverse events reported to the TGA for dabigatran June 2009 - Oct 2011, and the important messages given there. "The analysis of these reports shows that some of the bleeding adverse events occurred during the transition from warfarin to dabigatran; many of the adverse events are occurring in patients on the reduced dosage regimen; and the most common site of serious bleeding for dabigatran is the gastrointestinal tract, whereas for warfarin it is intracranial. Risk factors for bleeding: Age ≥ 75 years; Moderate renal impairment (30-50 mL/min) - severe renal impairment is a contraindication; Concomitant use of aspirin (approximately twice the risk), clopidogrel (approximately twice the risk), non-steroidal anti-inflammatory drugs including COX-2 inhibitors Monitoring renal function New recommendations for assessing renal function before starting dabigatran and during its use are now in place." http://www.tga.gov.au/hp/msu-2011-06.htm#pradaxa or http://www.theheart.org/article/1291757.do

These things are very relevant for patiënts and healthcare professionals.

What do you think?

Dr Jan Baekelandt GP during 33 years no conflicts of interest


 * With a number of these sources, there is a very real risk of falling foul of the guidance from WP:MEDRS. These are primary sources, often methodologically very weak. I am also concerned about WP:RECENTISM - a lot of safety signals from postmarketing surveillance turn out to be untrue. Do we need to alarm the general public about something that (in the fullness of time) will turn out to be wrong?
 * I'd prefer if we carried on discussing on Talk:Dabigatran, because it allows other editors to weigh in. JFW &#124; T@lk  16:54, 10 August 2012 (UTC)

Disambiguation link notification for August 27
Hi. Thank you for your recent edits. Wikipedia appreciates your help. We noticed though that you've added some links pointing to disambiguation pages. Such links are almost always unintended, since a disambiguation page is merely a list of "Did you mean..." article titles. Read the FAQ* Join us at the DPL WikiProject.


 * Dabigatran (check to confirm | fix with Dab solver)
 * added a link pointing to TTR


 * Rivaroxaban (check to confirm | fix with Dab solver)
 * added a link pointing to TTR

It's OK to remove this message. Also, to stop receiving these messages, follow these opt-out instructions. Thanks, DPL bot (talk) 11:18, 27 August 2012 (UTC)

New paragraph
Please don't use to begin a new paragraph. Two carriage returns is sufficient. JFW &#124; T@lk  20:13, 29 August 2012 (UTC)

Disambiguation link notification for September 4
Hi. Thank you for your recent edits. Wikipedia appreciates your help. We noticed though that when you edited Rivaroxaban, you added a link pointing to the disambiguation page VTE (check to confirm | fix with Dab solver). Such links are almost always unintended, since a disambiguation page is merely a list of "Did you mean..." article titles. Read the FAQ* Join us at the DPL WikiProject.

It's OK to remove this message. Also, to stop receiving these messages, follow these opt-out instructions. Thanks, DPL bot (talk) 11:05, 4 September 2012 (UTC)

Disambiguation link notification for September 11
Hi. Thank you for your recent edits. Wikipedia appreciates your help. We noticed though that you've added some links pointing to disambiguation pages. Such links are almost always unintended, since a disambiguation page is merely a list of "Did you mean..." article titles. Read the FAQ* Join us at the DPL WikiProject.


 * Apixaban (check to confirm | fix with Dab solver)
 * added a link pointing to P2Y


 * Dabigatran (check to confirm | fix with Dab solver)
 * added a link pointing to Ema

It's OK to remove this message. Also, to stop receiving these messages, follow these opt-out instructions. Thanks, DPL bot (talk) 10:52, 11 September 2012 (UTC)

Copy and pasting
All your edits appear to be. Doc James (talk · contribs · email) (if I write on your page reply on mine) 01:42, 21 July 2014 (UTC)

ArbCom elections are now open!
Hi, You appear to be eligible to vote in the current Arbitration Committee election. The Arbitration Committee is the panel of editors responsible for conducting the Wikipedia arbitration process. It has the authority to enact binding solutions for disputes between editors, primarily related to serious behavioural issues that the community has been unable to resolve. This includes the ability to impose site bans, topic bans, editing restrictions, and other measures needed to maintain our editing environment. The arbitration policy describes the Committee's roles and responsibilities in greater detail. If you wish to participate, you are welcome to review the candidates' statements and submit your choices on the voting page. For the Election committee, MediaWiki message delivery (talk) 16:55, 24 November 2015 (UTC)